Board of Director - Glenmark Pharmaceuticals

Home>
About Us>
Board of Directors

Board of Directors

Chairman & Managing Director

Glenn Saldanha

Glenn joined Glenmark in 1998 and subsequently became the Managing Director & CEO in 2000. He transformed Glenmark into a truly multinational company with revenues of over USD 1.5 Bn.

Glenn envisions discovering, developing and introducing India’s first innovative drug for the world. Under his leadership, Glenmark evolved from an Indian-branded generics business into a research-driven and innovation-led global organization.

Executive Director and Global Chief Financial Officer

V. S. Mani

Mani leads the organization’s worldwide Finance Operations, as well as Legal and Secretarial Functions. He has over thirty years of industry experience across treasury, taxation, accounting, financial planning and analysis, secretarial, legal, risk management, and investor relations.

Mani has also played a key role in mergers, acquisitions and spinouts of various companies in emerging and mature markets. Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. He has also held the position of Chief Financial Officer at Cipla.

Executive Director – Corporate Services

Cheryl Pinto

Cheryl has been Director of Corporate Services at Glenmark since October 1999 and is an Executive Member of the Board. With over three decades of experience in the pharmaceutical field, she currently heads the Company’s corporate services which comprises Human Resources (HR), Administration, Insurance, Information Technology (IT), Corporate Communications, and Corporate Social Responsibility (CSR) functions. Prior to Glenmark, she was an entrepreneur, establishing a pharmaceutical Company where she served as Managing Director for ten years.

Non-Executive Director

Blanche E. Saldanha

B.E.-Saldanha_0_0

Blanche is a Non-Executive Director and a member of the promoter group of Glenmark Pharmaceuticals Limited. Prior to this, she was the Director for Exports and managed Glenmark’s international operations from 1982 to 2005. During her 23-year tenure with the organization, she was responsible for developing and growing the Company’s export business.

Non-Executive Independent Director

Rajesh V. Desai

Rajesh-V.-Desai_0

Rajesh is a Non-Executive Independent Director at Glenmark Pharmaceuticals Limited. He has 37 years of rich experience, and was the Executive Director and Chief Financial Officer of Glenmark until 2016. Rajesh led the Finance, Legal and IT functions at Glenmark, and has contributed significantly to its growth story.

Non-Executive Independent Director M

Saira Ramasastry

ramasastry036-Edit1_0_0

Saira is a Non-Executive Independent Director at Glenmark Pharmaceuticals Limited. She has over two decades of experience in the Life Sciences industry, successfully building companies as an advisor, board member and operational executive. Saira is the Founder and Managing Partner of Life Sciences Advisory, LLC.

Non-Executive Independent Director

Dipankar Bhattacharjee

Dipankar Work Photo

Dipankar is a Non-Executive Independent Director at Glenmark Pharmaceuticals Limited. He has over three decades of global experience leading healthcare businesses across North America, Europe, APAC and MEA. Mr. Bhattacharjee was President & CEO – Global Generics Medicines at Teva Pharmaceutical Industries, and prior to that, he held senior leadership roles at Bausch & Lomb, Bank of America, and Nestlé. He currently advises investors on mergers and acquisitions in the European generics space.

Non-Executive Independent Director

Vijayalakshmi Iyer

vijayalakshmi

Vijayalakshmi is a Non-Executive Independent Director at Glenmark Pharmaceuticals Limited. She has nearly four decades of experience in the banking and finance sector in India. She retired as the Chairman and Managing Director of Bank of India in May 2015 where she played an instrumental role in structuring it as an umbrella institution offering a diverse range of banking and financial services. She also served as a member (finance and investment) at IRDAI from 2015 to 2017 where she played a significant role in the introduction and amendment of various regulations related to, inter alia, finance and accounts, corporate governance, mergers and acquisition, registration of new insurance companies and exposure of management.